RxDoctor Payments Data

Victoria Cupic, MD

Family Medicine · Scottsdale, AZNPI 1669421038

Payments from drug & device makers

$1,932in general payments, 2019–2025

Across 104 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$321
  • Revance Therapeutics, Inc.$274
  • Arbor Pharmaceuticals, Inc.$163
  • Kowa Pharmaceuticals America, Inc.$139
  • Lilly USA, LLC$137
  • Abbott$133
  • plus $764 from 19 others

What the payments were for

  • Food & beverage$1,90398%
  • Education$292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,932 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$138,485
Medicare patients
607
Services billed
2,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$46,868
JardianceEmpagliflozin24$36,071
EliquisApixaban31$35,000
MounjaroTirzepatide26$24,971
Breo ElliptaFluticasone/Vilanterol14$8,008
Xigduo XrDapaglifloz Propaned/Metformin13$5,594
Advair HfaFluticasone Propion/Salmeterol12$4,780
Atorvastatin Calcium327$2,829
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,611
Estradiol (Twice Weekly)Estradiol28$2,603
Levothyroxine Sodium256$2,362
Albuterol Sulfate HfaAlbuterol Sulfate66$2,231
ProgesteroneProgesterone, Micronized59$2,215
Rosuvastatin Calcium180$2,195
Losartan Potassium161$2,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$83$46,86841 claims
PfizerEliquis$70$35,00031 claims
Lilly USA, LLCMounjaro$137$24,97126 claims
AbbVieSynthroid$110$2,06728 claims
Almatica Pharma LLCSertraline Hcl$17$48054 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →